Targeting lysyl oxidase (LOX) overcomes chemotherapy resistance in triple negative breast cancer

Chemoresistance is a major obstacle in triple negative breast cancer (TNBC), the most aggressive breast cancer subtype. Here we identify hypoxia-induced ECM re-modeler, lysyl oxidase (LOX) as a key inducer of chemoresistance by developing chemoresistant TNBC tumors in vivo and characterizing their t...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Nat Commun
Autors principals: Saatci, Ozge, Kaymak, Aysegul, Raza, Umar, Ersan, Pelin G., Akbulut, Ozge, Banister, Carolyn E., Sikirzhytski, Vitali, Tokat, Unal Metin, Aykut, Gamze, Ansari, Suhail A., Dogan, Hayriye Tatli, Dogan, Mehmet, Jandaghi, Pouria, Isik, Aynur, Gundogdu, Fatma, Kosemehmetoglu, Kemal, Dizdar, Omer, Aksoy, Sercan, Akyol, Aytekin, Uner, Aysegul, Buckhaults, Phillip J., Riazalhosseini, Yasser, Sahin, Ozgur
Format: Artigo
Idioma:Inglês
Publicat: Nature Publishing Group UK 2020
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7229173/
https://ncbi.nlm.nih.gov/pubmed/32415208
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41467-020-16199-4
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars